333 related articles for article (PubMed ID: 29848257)
1. Immunomodulatory Therapies for Renal Cell Carcinoma.
Liu M; Wu H; Shangguan D; Jiang Y; Li X; Liu S; Zhou B; Yin T; Gong Z
Protein Pept Lett; 2018; 25(6):534-547. PubMed ID: 29848257
[TBL] [Abstract][Full Text] [Related]
2. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in renal cell cancer immunotherapy.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
5. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
[TBL] [Abstract][Full Text] [Related]
6. Emerging immunotherapies for renal cell carcinoma.
Escudier B
Ann Oncol; 2012 Sep; 23 Suppl 8():viii35-40. PubMed ID: 22918926
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Biswas S; Eisen T
Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
[TBL] [Abstract][Full Text] [Related]
8. TroVax(®) vaccine therapy for renal cell carcinoma.
Zhang RT; Bines SD; Ruby C; Kaufman HL
Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in immunotherapy for kidney cancer.
Ball MW; Allaf ME; Drake CG
Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
[TBL] [Abstract][Full Text] [Related]
10. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
11. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
Bukowski RM
Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
13. Vaccines in renal cell carcinoma.
Kübler H; Vieweg J
Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of metastatic renal cell cancer.
Fishman M; Seigne J
Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
17. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
Guida M; Colucci G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi149-52. PubMed ID: 17591810
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cell cancer treatments.
Sternberg CN
Drugs Today (Barc); 2003; 39 Suppl C():39-59. PubMed ID: 14988745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]